Pretargeting for imaging and therapy in oncological nuclear medicine

BACKGROUND: Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Clément, Bodet-Milin, Caroline, Rousseau, Caroline, Faivre-Chauvet, Alain, Kraeber-Bodéré, Françoise, Barbet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824696/
https://www.ncbi.nlm.nih.gov/pubmed/29503847
http://dx.doi.org/10.1186/s41181-017-0026-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824696/
https://www.ncbi.nlm.nih.gov/pubmed/29503847
http://dx.doi.org/10.1186/s41181-017-0026-8

Ejemplares similares